Trials@uspto.gov
571-272-7822

Paper 7
Date: October 13, 2020

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LIQUIDIA TECHNOLOGIES, INC.,
Petitioner,

v.

UNITED THERAPEUTICS CORPORATION,
Patent Owner.

IPR2020-00769
Patent 9,593,066 B2

Before ERICA A. FRANKLIN, ZHENYU YANG, and JOHN E. SCHNEIDER, *Administrative Patent Judges.*

YANG, *Administrative Patent Judge*.

DECISION
Denying Institution of *Inter Partes* Review
35 U.S.C. § 314

INTRODUCTION

Liquidia Technologies, Inc. ("Petitioner") filed a Petition (Paper 1 ("Pet.")), seeking an *inter partes* review of claims 1–10 of U.S. Patent No. 9,593,066 B2 (Ex. 1001, "the '066 patent"). United Therapeutics Corporation ("Patent Owner") filed a Preliminary Response (Paper 6 ("Prelim. Resp.")).

We have authority under 35 U.S.C. § 314, which provides that an *inter partes* review may not be instituted "unless . . . there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition." 35 U.S.C. § 314(a).

For the reasons provided below, we determine Petitioner has not demonstrated a reasonable likelihood that it would prevail with respect to at least one of the claims challenged in the Petition. Accordingly, we deny institution of an *inter partes* review.

Related Matters

Patent Owner asserted the '066 patent against Petitioner in *United Therapeutics Corporation v. Liquidia Technologies, Inc.*, Case No. 1:20-cv-00755 (D. Del.). Paper 5, 1.

Petitioner filed IPR2020-00770, challenging the claims of U.S. Patent No. 9,604,901, a patent in the same family as the '066 patent. *Id.* Together with this Decision, we concurrently issue a decision in that case, instituting an *inter partes* review. IPR2020-00770, Paper 7.

U.S. Patent No. 8,497,393 (Ex. 1004, "the '393 patent") is a parent of the '901 patent. Ex. 1001, Code (60). The '393 patent was the subject of *SteadyMed Ltd. v. United Therapeutics Corp.*, IPR2016-00006 ("the '393

IPR"). In that case, the Board held that claims 1–22 of the '393 patent are unpatentable (IPR2016-00006, Paper 82 (PTAB March 31, 2017) ("the '393 Decision" or "the '393 Dec."), and the Federal Circuit affirmed (*United Therapeutics Corp. v. SteadyMed Ltd.*, 702 Fed.App'x. 990 (Fed. Cir. 2017)).

The '066 Patent

The '066 patent relates to "an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil." Ex. 1001, Abstract.

Treprostinil was a known, useful pharmaceutical compound. *Id.* at 1:35–65, *see also id.* at 27 ("Treprostinil [is] the active ingredient in Remodulin®."). Before the '901 patent, treprostinil had been prepared as described in Moriarty[1] and other prior-art references. *Id.* at 1:28–32. According to the '066 patent, because treprostinil is "of great importance from a medicinal point of view, a need exists for an efficient process to synthesize th[is] compound[] on a large scale suitable for commercial production." *Id.* at 1:66–2:3.

The '066 patent discloses "a process for the preparation of a compound having formula IV, or a hydrate, solvate, or pharmaceutically acceptable salt thereof." *Id.* at 8:20–22. Petitioner represents that Formula IV

[1] Moriarty et al., *The Intramolecular Asymmetric Pauson-Khand Cyclization as a Novel and General Stereoselective Route to Benzindene Prostacyclins: Synthesis of UT-15 (Treprostinil)*, 69 J. ORG. CHEM. 1890–1902 (2004) (Ex. 1009). Moriarty is one of the two prior-art references asserted in this proceeding.

is treprostinil. Pet. 33; Ex. 1002 ¶ 31. Formula IV has the following structure:



The figure above shows the structure of Formula IV. *Id.* at 8:25–37.

The process of the '066 patent comprises

(a) alkylating a compound of structure V with an alkylating agent such as $ClCH_2CN$ to produce a compound of formula VI,
(b) hydrolyzing the product of step (a) with a base such as KOH,
(c) contacting the product of step (b) with a base B such as diethanolamine to for a salt of the following structure, and
(d) reacting the salt from step (b) with an acid such as HCl to form the compound of formula IV.

Id. at 8:40–9:21. Structure V, formula VI, and the salt formed in step (c) have the following structures:





The figures above show the structures of structure V, formula VI, and the salt formed in step (c). *Id.* at 8:45–65, 9:8–18. The ’066 patent states that “[i]n one embodiment, the purity of compound of formula IV is at least 90.0%, 95.0%, 99.0%, 99.5%.” *Id.* at 9:23–24.

According to the ’066 patent:

> The quality of treprostinil produced according to this invention is excellent. The purification of benzindene nitrile by column chromatography is eliminated. The impurities carried over from intermediate steps (i.e. alkylation of triol and hydrolysis of benzindene nitrile) are removed during the carbon treatment and the salt formation step. Additional advantages of this process are: (a) crude treprostinil salts can be stored as raw material at ambient temperature and can be converted to treprostinil by simple acidification with diluted hydrochloric acid, and (b) the treprostinil salts can be synthesized from the solution of treprostinil without isolation. This process provides better quality of final product as well as saves significant amount of solvents and manpower in purification of intermediates.

Id. at 17:27–40, *see also id.* at 5:57–6:3 (the same).

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.